Literature DB >> 14991543

Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans.

Tomonari Takahira1, Yoshinao Oda, Sadafumi Tamiya, Hidetaka Yamamoto, Kenichi Kawaguchi, Chikashi Kobayashi, Shinya Oda, Yukihide Iwamoto, Masazumi Tsuneyoshi.   

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a dermal and subcutaneous tumor categorized as a tumor of intermediate malignancy, and its progression in some cases to fibrosarcoma is well known. However, molecular analysis of tumor progression has been limited. The present study investigated microsatellite instability (MSI) of 7 microsatellite markers through high-resolution microsatellite analysis in addition to a mutational analysis of the p53 gene in 44 tumors in 36 patients. The patients were divided into 2 groups: 9 patients with a fibrosarcomatous component in the primary or recurrent/metastasized tumor, designated as the DFSP+FS group, and the remaining 27 patients, designated as the DFSP group. Cases in which the percentage of markers with an additional peak among the markers successfully analyzed was more than 30% was considered MSI high (MSI-H); cases in which microsatellites were stable at all of the successfully examined markers were considered microsatellite stable (MSS); and the remaining cases were considered MSI low (MSI-L). MSI-H cases were observed more frequently in the DFSP+FS group (4 of 9 cases) than in the DFSP group (1 of 27 cases) (P = 0.028, Fischer's exact test). The MSI status of recurrent or metastatic tumors in both the DFSP+FS and the DFSP groups was the same as that in the corresponding primary neoplasms. Furthermore, there was no difference in MSI status between an ordinary DFSP area and a fibrosarcomatous area in 7 tumors that exhibited both areas. p53 mutational analysis revealed 10 point mutations, composed of 4 missense mutations and 6 silent mutations, in 6 of 36 cases (16.7%). A missense mutation was more frequently observed in the DFSP+FS group (3 of 4) than in the DFSP group (1 of 4). Among 3 cases of a missense mutation in the DFSP+FS group, 2 had a mutation only in a fibrosarcomatous area and 1 had a mutation only in a metastatic tumor progressing to fibrosarcoma. These results suggest that MSI and p53 mutations are involved in tumor progression of DFSP to fibrosarcoma as early and late events, respectively.

Entities:  

Mesh:

Year:  2004        PMID: 14991543     DOI: 10.1016/j.humpath.2003.09.016

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

Review 1.  Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.

Authors:  Takeshi Iwasaki; Hidetaka Yamamoto; Yoshinao Oda
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

2.  Coamplification of 12q15 and 12p13 and homozygous CDKN2A/2B deletion: synergistic role of fibrosarcomatous transformation in dermatofibrosarcoma protuberans with a cryptic COL1A1-PDGFB fusion.

Authors:  Yang Lu; Tao Li; Min Chen; Heng Peng; Tianhai Du; Yan Qiu; Hongying Zhang
Journal:  Virchows Arch       Date:  2022-02-16       Impact factor: 4.535

3.  Neoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literature.

Authors:  Mashaal Dhir; David G Crockett; Todd M Stevens; Peter T Silberstein; William J Hunter; Jason M Foster
Journal:  Clin Sarcoma Res       Date:  2014-08-06

Review 4.  Epigenetics of Cutaneous Sarcoma.

Authors:  Emi Mashima; Yu Sawada
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

Review 5.  Cutaneous soft tissue sarcomas: survival-related factors.

Authors:  Areti Gkantaifi; Alexandros Diamantis; Davide Mauri; Ioanna Nixon; Anastassios Kyriazoglou; Ioannis Baloyiannis; Nikolaos Tsoukalas; Nikolaos Charalampakis; Dimitrios Schizas; Francesco Cuccia; Filippo Alongi; Ramon Andrade de Mello; George Iliadis; Konstantinos Kamposioras; Michalis Mazonakis; Maria Tolia
Journal:  Arch Dermatol Res       Date:  2021-07-17       Impact factor: 3.033

Review 6.  Dermatofibrosarcoma protuberans: from translocation to targeted therapy.

Authors:  Jonathan Noujaim; Khin Thway; Cyril Fisher; Robin L Jones
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

7.  Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.

Authors:  Kenji Tsuchihashi; Hitoshi Kusaba; Yuichi Yamada; Yuta Okumura; Hozumi Shimokawa; Masato Komoda; Keita Uchino; Tomoyasu Yoshihiro; Nobuhiro Tsuruta; Fumiyasu Hanamura; Kyoko Inadomi; Mamoru Ito; Kosuke Sagara; Michitaka Nakano; Kenta Nio; Shuji Arita; Hiroshi Ariyama; Kenichi Kohashi; Ryuji Tominaga; Yoshinao Oda; Koichi Akashi; Eishi Baba
Journal:  Mol Clin Oncol       Date:  2017-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.